CD38 and plasma cell myeloma: By evaluating and comparing several formulations, we successfully identified the most potent CD38-targeted formulation that clearly outperformed both free drug- and the nontargeted drug-loaded nanoparticles, making them desirable candidates for clinical testing in multiple myeloma tumors that express CD38.